We aim to develop, evaluate and disseminate new tools for evaluation of drug resistance in L. donovani as well as innovative methodologies for monitoring Kala-Azar treatment effectiveness in routine conditions.
Develop an innovative approach for monitoring the effectiveness of Kala-Azar drug treatments in routine conditions (WP2: 48 months).Develop new tools for the assessment of natural resistance to MIL and SSG in L. donovani parasites. We will document the genomic background and molecular/biological mechanisms leading to natural resistance to MIL and SSG, establish the basis for simplified monitoring assays and evaluate their performance on clinical samples (WPs 5-7 and 9: 48 months).Recruit and follow-up cohorts of patients treated with MIL in India and Nepal, provide complete clinical documentation and obtain pre-treatment samples as well as samples from treatment failure for validation of the above mentioned assays (WPs 3-4: 36 months).Explore, in experimental conditions, pathways leading to parasite resistance to Paromomycin, a drug which is currently in phase IV (WP8: 48 months).Build models to understand the dynamics of the past spread of parasite SSG resistance as a model for resistance to MIL or future drugs (WPs 10 and 12: 24 and 36 months).Study the impact of drug resistance on the parasite fitness (WP11: 48 months).To get research results into policy at regional level and disseminate the generated knowledge and the validated tools in other regions in the world endemic for leishmaniasis (WPs 13-14: 48 months).
|Effective start/end date||1/11/08 → 30/04/13|
- European Commission: €4,972,949.00